More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.
Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.
When patients with pacemakers die, what happens to the device? Typically, it ends up being discarded and forgotten—they were designed to be single-use devices, after all—but that does not have to be the case.
